Do Black Boxes Work? US FDA Survey Would Test Impact On Prescribers
Depending on who you ask, black box warnings can fail to curb inappropriate prescribing or scare off patients who would benefit from an effective therapy. FDA is proposing a provider survey to find out what perceptions really are.
You may also be interested in...
US FDA proposes studies to look at the impact of disclosure of a product’s secondary claims and biosimilar designation; disclosure about unapproved uses; and the impact of citing a drug’s multiple indications in TV ads.
Despite advisory committee pressure, US FDA stands firm against imposing REMS targeted at gout drug’s cardiovascular risks; however, Takeda must conduct utilization study to see if labeling changes impact prescribing patterns.
Those patients need more options for smoking cessation, Pfizer says, but that is the group FDA most worries about when deciding whether to remove its boxed warning.